Nanoparticle-Based Gene Therapy Intervention for Stroke Treatment: A Systematic Review

Author(s): Sorayya Ghasemi, Kimia Alavian, Firoozeh Alavian*

Journal Name: Current Gene Therapy

Volume 20 , Issue 5 , 2020


  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Ischemic stroke is one of the main causes of mortality in advanced societies. Although gene therapy can be helpful, delivering gene therapy agents is challenging. Nanotechnology can enhance the potential therapeutic effects and the efficiency of gene therapy for some brain disorders. The present systematic review was conducted based on the PRISMA protocol to investigate the possible therapeutic effects of nanoparticles as the carriers of gene therapy agents in stroke therapy. Relevant keywords were used to search from ISI Web of Science, PubMed, and Scopus for relevant publications up to April 24, 2020. The selected articles were assessed using certain scores on the quality of the articles. Data extraction and quality judgment were carried out by the present reviewers. Of 130 articles retrieved, seven met the inclusion criteria and were, therefore, included in the final analysis. The outcome of the reviewing process revealed that depending on the selection of the target genes, stroke gene therapies have acceptable therapeutic consequences. The nanoparticles could be used to carry the gene therapy agents that are efficient targeting in stroke treatment. Also, it appears that the use of nanoparticles such as PEGylation and PAMAM, can be a valuable option to intensify the efficiency and specific targeting of stroke location. In conclusion, due to the inability of brain regeneration and the importance of genes in stroke-related complications, gene therapy seems to be a suitable treatment strategy. The use of suitable nanoparticles for transportation ensures the efficiency and usefulness of this method.

Keywords: Nanoparticle, gene therapy, stroke, brain, animal model, PEGylation.

[1]
Katan M, Luft A. Global burden of stroke. Semin Neurol 2018; 38(2): 208-11.
[http://dx.doi.org/10.1055/s-0038-1649503] [PMID: 29791947]
[2]
Chen L, Gao X. The application of nanoparticles for neuroprotection in acute ischemic stroke. Ther Deliv 2017; 8(10): 915-28.
[http://dx.doi.org/10.4155/tde-2017-0023] [PMID: 28944741]
[3]
Bharadwaj VN, Nguyen DT, Kodibagkar VD, Stabenfeldt SE. Nanoparticle-based therapeutics for brain injury. Adv Healthc Mater 2018; 7(1): 1700668.
[http://dx.doi.org/10.1002/adhm.201700668] [PMID: 29034608]
[4]
Han L, Cai Q, Tian D, et al. Targeted drug delivery to ischemic stroke via chlorotoxin-anchored, lexiscan-loaded nanoparticles. Nanomedicine (Lond) 2016; 12(7): 1833-42.
[http://dx.doi.org/10.1016/j.nano.2016.03.005] [PMID: 27039220]
[5]
Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release 2016; 235: 34-47.
[http://dx.doi.org/10.1016/j.jconrel.2016.05.044] [PMID: 27208862]
[6]
Bharadwaj VN, Lifshitz J, Adelson PD, Kodibagkar VD, Stabenfeldt SE. Temporal assessment of nanoparticle accumulation after experimental brain injury: Effect of particle size. Sci Rep 2016; 6: 29988.
[http://dx.doi.org/10.1038/srep29988] [PMID: 27444615]
[7]
Guo X, Deng G, Liu J, et al. Thrombin-responsive, brain-targeting nanoparticles for improved stroke therapy. ACS Nano 2018; 12(8): 8723-32.
[http://dx.doi.org/10.1021/acsnano.8b04787] [PMID: 30107729]
[8]
Latour LL, Kang DW, Ezzeddine MA, Chalela JA, Warach S. Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol 2004; 56(4): 468-77.
[http://dx.doi.org/10.1002/ana.20199] [PMID: 15389899]
[9]
Warach S, Latour LL. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke 2004; 35(11)(Suppl. 1): 2659-61.
[http://dx.doi.org/10.1161/01.STR.0000144051.32131.09] [PMID: 15472105]
[10]
Dong X. Current strategies for brain drug delivery. Theranostics 2018; 8(6): 1481-93.
[http://dx.doi.org/10.7150/thno.21254] [PMID: 29556336]
[11]
Soni S, Ruhela RK, Medhi B. Nanomedicine in central nervous system (CNS) disorders: a present and future prospective. Adv Pharm Bull 2016; 6(3): 319-35.
[http://dx.doi.org/10.15171/apb.2016.044] [PMID: 27766216]
[12]
Sim TM, Tarini D, Dheen ST, Bay BH, Srinivasan DK. Nanoparticle-based technology approaches to the management of neurological disorders. Int J Mol Sci 2020; 21(17): 6070.
[http://dx.doi.org/10.3390/ijms21176070] [PMID: 32842530]
[13]
Shcharbina N, Shcharbin D, Bryszewska M. Nanomaterials in stroke treatment: perspectives. Stroke 2013; 44(8): 2351-5.
[http://dx.doi.org/10.1161/STROKEAHA.113.001298] [PMID: 23715957]
[14]
Alavian F. Drug abuse treatment through gene manipulation using nanomedicine. Curr Pharmacogenomics Person Med 2018; 16(3): 182-91.
[http://dx.doi.org/10.2174/1875692117666181207120751]
[15]
De Rosa G, Salzano G, Caraglia M, Abbruzzese A. Nanotechnologies: a strategy to overcome blood-brain barrier. Curr Drug Metab 2012; 13(1): 61-9.
[http://dx.doi.org/10.2174/138920012798356943] [PMID: 22292810]
[16]
Nozohouri S, Sifat AE, Vaidya B, Abbruscato TJ. Novel approaches for the delivery of therapeutics in ischemic stroke. Drug Discov Today 2020; 25(3): 535-51.
[http://dx.doi.org/10.1016/j.drudis.2020.01.007] [PMID: 31978522]
[17]
Alavian F, Shams N. Oral and intranasal administration of nanoparticles in the cerebral ischemia treatment; Considering the advantages and disadvantages. Curr Clin Pharmacol 2019; 14: 1-10.
[http://dx.doi.org/10.2174/1574884714666190704115345] [PMID: 31272358]
[18]
Naqvi S, Panghal A, Flora SJS. Nanotechnology: A promising approach for delivery of neuroprotective drugs. Front Neurosci 2020; 14: 494.
[http://dx.doi.org/10.3389/fnins.2020.00494] [PMID: 32581676]
[19]
Wang GY, Rayner SL, Chung R, Shi BY, Liang X-J. Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis. Mater Today Bio 2020; 6: 100055.
[http://dx.doi.org/10.1016/j.mtbio.2020.100055] [PMID: 32529183]
[20]
Zhang W, Wang W, Yu DX, Xiao Z, He Z. Application of nanodiagnostics and nanotherapy to CNS diseases. Nanomedicine (Lond) 2018; 13(18): 2341-71.
[http://dx.doi.org/10.2217/nnm-2018-0163] [PMID: 30088440]
[21]
Obermeyer JM, Ho E, Gracias A, Shoichet MS. Influencing neuroplasticity in stroke treatment with advanced biomaterials-based approaches. Adv Drug Deliv Rev 2019; 148: 204-18.
[http://dx.doi.org/10.1016/j.addr.2018.12.012] [PMID: 30579882]
[22]
Roy I, Stachowiak MK, Bergey EJ. Nonviral gene transfection nanoparticles: function and applications in the brain. Nanomedicine (Lond) 2008; 4(2): 89-97.
[http://dx.doi.org/10.1016/j.nano.2008.01.002] [PMID: 18313990]
[23]
Gunnett CA, Heistad DD. The future of gene therapy for stroke. Curr Hypertens Rep 2001; 3(1): 36-40.
[http://dx.doi.org/10.1007/s11906-001-0076-9] [PMID: 11177706]
[24]
Amani H, Habibey R, Shokri F, et al. Selenium nanoparticles for targeted stroke therapy through modulation of inflammatory and metabolic signaling. Sci Rep 2019; 9(1): 6044.
[http://dx.doi.org/10.1038/s41598-019-42633-9] [PMID: 30988361]
[25]
Liu C, Zhang N. Nanoparticles in gene therapy principles, prospects, and challenges. Prog Mol Biol Transl Sci 2011; 104: 509-62.
[http://dx.doi.org/10.1016/B978-0-12-416020-0.00013-9] [PMID: 22093228]
[26]
Kyle S, Saha S. Nanotechnology for the detection and therapy of stroke. Adv Healthc Mater 2014; 3(11): 1703-20.
[http://dx.doi.org/10.1002/adhm.201400009] [PMID: 24692428]
[27]
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6(7): e1000100.
[http://dx.doi.org/10.1371/journal.pmed.1000100] [PMID: 19621070]
[28]
Viseu T, Lopes CM, Fernandes E, Oliveira MECDR, Lúcio M. A systematic review and critical analysis of the role of graphene-based nanomaterialsin cancer theranostics. Pharmaceutics 2018; 10(4): 282-326.
[http://dx.doi.org/10.3390/pharmaceutics10040282] [PMID: 30558378]
[29]
Au M, Emeto TI, Power J, Vangaveti VN, Lai HC. Emerging therapeutic potential of nanoparticles in pancreatic cancer: a systematic review of clinical trials. Biomedicines 2016; 4(3): 20.
[http://dx.doi.org/10.3390/biomedicines4030020] [PMID: 28536387]
[30]
Oh J, Lee J, Piao C, Jeong JH, Lee M. A self-assembled DNA-nanoparticle with a targeting peptide for hypoxia-inducible gene therapy of ischemic stroke. Biomater Sci 2019; 7(5): 2174-90.
[http://dx.doi.org/10.1039/C8BM01621F] [PMID: 30900719]
[31]
Deng L, Zhang F, Wu Y, et al. RGD-modified nanocarrier-mediated targeted delivery of HIF-1α-AA plasmid DNA to cerebrovascular endothelial cells for ischemic stroke treatment. ACS Biomater Sci Eng 2019; 5(11): 6254-64.
[http://dx.doi.org/10.1021/acsbiomaterials.9b01362]
[32]
Jeon P, Choi M, Oh J, Lee M. Dexamethasone-conjugated polyamidoamine dendrimer for delivery of the heme oxygenase-1 gene into the ischemic brain. Macromol Biosci 2015; 15(7): 1021-8.
[http://dx.doi.org/10.1002/mabi.201500058] [PMID: 26033925]
[33]
Mätlik K, Abo-Ramadan U, Harvey BK, Arumäe U, Airavaara M. AAV-mediated targeting of gene expression to the peri-infarct region in rat cortical stroke model. J Neurosci Methods 2014; 236: 107-13.
[http://dx.doi.org/10.1016/j.jneumeth.2014.08.014] [PMID: 25152446]
[34]
Shi W, Mei H, Deng J, et al. The delivery of thrombi-specific nanoparticles incorporating oligonucleotides into injured cerebrovascular endothelium. Biomaterials 2013; 34(16): 4128-36.
[http://dx.doi.org/10.1016/j.biomaterials.2013.02.013] [PMID: 23465828]
[35]
An S, Kuang Y, Shen T, et al. Brain-targeting delivery for RNAi neuroprotection against cerebral ischemia reperfusion injury. Biomaterials 2013; 34(35): 8949-59.
[http://dx.doi.org/10.1016/j.biomaterials.2013.07.060] [PMID: 23968852]
[36]
Oh J, Kim S-M, Lee E-H, et al. Messenger RNA/polymeric carrier nanoparticles for delivery of heme oxygenase-1 gene in the post-ischemic brain. Biomater Sci 2020; 8(11): 3063-71.
[http://dx.doi.org/10.1039/D0BM00076K] [PMID: 32348398]
[37]
Ornello R, Degan D, Tiseo C, et al. Distribution and temporal trends from 1993 to 2015 of ischemic stroke subtypes: a systematic review and meta-analysis. Stroke 2018; 49(4): 814-9.
[http://dx.doi.org/10.1161/STROKEAHA.117.020031] [PMID: 29535272]
[38]
Jeffers MS, Karthikeyan S, Gomez-Smith M, et al. Does stroke rehabilitation really matter? Part B: an algorithm for prescribing an effective intensity of rehabilitation. Neurorehabil Neural Repair 2018; 32(1): 73-83.
[http://dx.doi.org/10.1177/1545968317753074] [PMID: 29334831]
[39]
Fukuta T, Asai T, Yanagida Y, et al. Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke. FASEB J 2017; 31(5): 1879-90.
[http://dx.doi.org/10.1096/fj.201601209R] [PMID: 28082354]
[40]
Feczkó T, Piiper A, Ansar S, et al. Stimulating brain recovery after stroke using theranostic albumin nanocarriers loaded with nerve growth factor in combination therapy. J Control Release 2019; 293: 63-72.
[http://dx.doi.org/10.1016/j.jconrel.2018.11.017] [PMID: 30458203]
[41]
Liu Y, Ai K, Ji X, et al. Comprehensive insights into the multi-antioxidative mechanisms of melanin nanoparticles and their application to protect brain from injury in ischemic stroke. J Am Chem Soc 2017; 139(2): 856-62.
[http://dx.doi.org/10.1021/jacs.6b11013] [PMID: 27997170]
[42]
Celap I, Nikolac Gabaj N, Demarin V, Basic Kes V, Simundic A-M. Genetic and lifestyle predictors of ischemic stroke severity and outcome. Neurol Sci 2019; 40(12): 2565-72.
[http://dx.doi.org/10.1007/s10072-019-04006-y] [PMID: 31327072]
[43]
Szentirmai O, Carter BS. Genetic and cellular therapies for cerebral infarction. Neurosurgery 2004; 55(2): 283-6.
[http://dx.doi.org/10.1227/01.NEU.0000129681.85731.00] [PMID: 15271234]
[44]
Zhang Q, Chen W, Chen S, Li S, Wei D, He W. Identification of key genes and upstream regulators in ischemic stroke. Brain Behav 2019; 9(7): e01319.
[http://dx.doi.org/10.1002/brb3.1319] [PMID: 31168961]
[45]
Chen Y-C, Ma N-X, Pei Z-F, et al. NeuroD1 AAV-based gene therapy for functional brain repair after ischemic injury through in vivo astrocyte-to-neuron conversion. Mol Ther 2020; 28(1): 217-34.
[http://dx.doi.org/10.1016/j.ymthe.2019.09.003] [PMID: 31551137]
[46]
Sharma HS, Sharma A. Nanoparticles aggravate heat stress induced cognitive deficits, blood-brain barrier disruption, edema formation and brain pathology. Prog Brain Res 2007; 162: 245-73.
[http://dx.doi.org/10.1016/S0079-6123(06)62013-X] [PMID: 17645923]
[47]
Vega-Villa KR, Takemoto JK, Yáñez JA, Remsberg CM, Forrest ML, Davies NM. Clinical toxicities of nanocarrier systems. Adv Drug Deliv Rev 2008; 60(8): 929-38.
[http://dx.doi.org/10.1016/j.addr.2007.11.007] [PMID: 18313790]
[48]
Alkaff SA, Radhakrishnan K, Nedumaran AM, Liao P, Czarny B. Nanocarriers for stroke therapy: advances and obstacles in translating animal studies. Int J Nanomedicine 2020; 15: 445-64.
[http://dx.doi.org/10.2147/IJN.S231853] [PMID: 32021190]
[49]
Tsou YH, Zhang XQ, Zhu H, Syed S, Xu X. Drug delivery to the brain across the blood–brain barrier using nanomaterials. Small 2017; 13(43): 1701921.
[http://dx.doi.org/10.1002/smll.201701921] [PMID: 29045030]
[50]
Mali S. Delivery systems for gene therapy. Indian J Hum Genet 2013; 19(1): 3-8.
[http://dx.doi.org/10.4103/0971-6866.112870] [PMID: 23901186]
[51]
Amreddy N, Babu A, Muralidharan R, et al. Recent advances in nanoparticle-based cancer drug and gene delivery. Adv Cancer Res 2018; 137: 115-70.
[http://dx.doi.org/10.1016/bs.acr.2017.11.003] [PMID: 29405974]
[52]
Hernandez Y, González-Pastor R, Belmar-Lopez C, Mendoza G, Jesus M, Martin-Duque P. Gold nanoparticle coatings as efficient adenovirus carriers to non-infectable stem cells. RSC Advances 2019; 9(3): 1327-34.
[http://dx.doi.org/10.1039/C8RA09088B]
[53]
Bankiewicz K, Cunningham J, Eberling JL. Methods of treating central nervous system disorders using viral vectors. Google Patents US 9492415B2, 2005.
[54]
Choudhury SR, Hudry E, Maguire CA, Sena-Esteves M, Breakefield XO, Grandi P. Viral vectors for therapy of neurologic diseases. Neuropharmacology 2017; 120: 63-80.
[http://dx.doi.org/10.1016/j.neuropharm.2016.02.013] [PMID: 26905292]
[55]
ud Din F, Aman W, Ullah I, et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine 2017; 12: 7291-309.
[http://dx.doi.org/10.2147/IJN.S146315]
[56]
Kunzmann A, Andersson B, Thurnherr T, Krug H, Scheynius A, Fadeel B. Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation. Biochim Biophys Acta 2011; 1810(3): 361-73.
[http://dx.doi.org/10.1016/j.bbagen.2010.04.007] [PMID: 20435096]
[57]
Jain K, Kesharwani P, Gupta U, Jain NK. Dendrimer toxicity: Let’s meet the challenge. Int J Pharm 2010; 394(1-2): 122-42.
[http://dx.doi.org/10.1016/j.ijpharm.2010.04.027] [PMID: 20433913]
[58]
Maynard AD, Warheit DB, Philbert MA. The new toxicology of sophisticated materials: nanotoxicology and beyond. Toxicol Sci 2011; 120(Suppl. 1): S109-29.
[http://dx.doi.org/10.1093/toxsci/kfq372] [PMID: 21177774]
[59]
Zhang J, Tang H, Liu Z, Chen B. Effects of major parameters of nanoparticles on their physical and chemical properties and recent application of nanodrug delivery system in targeted chemotherapy. Int J Nanomedicine 2017; 12: 8483-93.
[http://dx.doi.org/10.2147/IJN.S148359] [PMID: 29238188]
[60]
Choi HS, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol 2007; 25(10): 1165-70.
[http://dx.doi.org/10.1038/nbt1340] [PMID: 17891134]
[61]
Euliss LE, DuPont JA, Gratton S, DeSimone J. Imparting size, shape, and composition control of materials for nanomedicine. Chem Soc Rev 2006; 35(11): 1095-104.
[http://dx.doi.org/10.1039/b600913c] [PMID: 17057838]
[62]
Li Y, Yue T, Yang K, Zhang X. Molecular modeling of the relationship between nanoparticle shape anisotropy and endocytosis kinetics. Biomaterials 2012; 33(19): 4965-73.
[http://dx.doi.org/10.1016/j.biomaterials.2012.03.044] [PMID: 22483010]
[63]
Lin J, Li X, Yang W, Li Z, Lu S, Lei Q. The effects of nanoparticles with different shapes on the interface bond energy in a polyimide/KTa0.5Nb0.5O3 composite. Mater Res Innov 2015; 19(Suppl. 5): 292-5.
[http://dx.doi.org/10.1179/1432891714Z.0000000001095]
[64]
Yang NJ, Hinner MJ. Getting across the cell membrane: an overview for small molecules, peptides, and proteins. Methods Mol Biol 2015; 1266: 29-53.
[http://dx.doi.org/10.1007/978-1-4939-2272-7_3] [PMID: 25560066]
[65]
Chen L, Mccrate JM, Lee JCM, Li H. The role of surface charge on the uptake and biocompatibility of hydroxyapatite nanoparticles with osteoblast cells. Nanotechnology 2011; 22(10): 105708.
[http://dx.doi.org/10.1088/0957-4484/22/10/105708] [PMID: 21289408]
[66]
Behzadi S, Serpooshan V, Tao W, et al. Cellular uptake of nanoparticles: journey inside the cell. Chem Soc Rev 2017; 46(14): 4218-44.
[http://dx.doi.org/10.1039/C6CS00636A] [PMID: 28585944]
[67]
Fröhlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine 2012; 7: 5577-91.
[http://dx.doi.org/10.2147/IJN.S36111] [PMID: 23144561]
[68]
Nel AE, Mädler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009; 8(7): 543-57.
[http://dx.doi.org/10.1038/nmat2442] [PMID: 19525947]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 5
Year: 2020
Published on: 11 December, 2020
Page: [373 - 382]
Pages: 10
DOI: 10.2174/1566523220666201012150130
Price: $65

Article Metrics

PDF: 26
HTML: 1